-
Product Insights
NewLikelihood of Approval Analysis for Osteoarthritis Pain
Overview How likely is it that the drugs in Osteoarthritis Pain will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osteoarthritis Pain Overview Osteoarthritis pain, the hallmark symptom of this degenerative joint...
-
Thematic Analysis
NewPublishing Sector Scorecard, Q1 2024 Update – Thematic Intelligence
AI continues to disrupt the publishing industry, and thus, the theme appears to be where the most progress is happening. To cope with the winds of change, publishers are holding AI-related conferences, building AI teams, and enhancing their offerings with AI, including launching new AI features like chatbots to improve user experiences.
-
Product Insights
NewLikelihood of Approval Analysis for Age Related Macular Degeneration
Overview How likely is it that the drugs in Age Related Macular Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Age Related Macular Degeneration Overview Macular degeneration, also known as...
-
Product Insights
NewLikelihood of Approval Analysis for Generalized Anxiety Disorder (GAD)
Overview How likely is it that the drugs in Generalized Anxiety Disorder (GAD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Generalized Anxiety Disorder (GAD) Overview Generalized anxiety disorder is a...
-
Product Insights
NewLikelihood of Approval Analysis for Dementia Associated With Alzheimer’s Disease
Overview How likely is it that the drugs in Dementia Associated With Alzheimer's Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dementia Associated With Alzheimer's Disease Overview Alzheimer's disease (AD)...
-
Product Insights
NewLikelihood of Approval Analysis for Lennox-Gastaut Syndrome
Overview How likely is it that the drugs in Lennox-Gastaut Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lennox-Gastaut Syndrome Overview Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy...
-
Product Insights
NewLikelihood of Approval Analysis for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Overview How likely is it that the drugs in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Overview Systemic-onset...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levetiracetam ER in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levetiracetam ER in Psychosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levetiracetam ER in Psychosis Drug Details: Levetiracetam ER (AGB-101) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Obicetrapib in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Obicetrapib in Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obicetrapib in Dyslipidemia Drug Details: Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cagrilintide in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cagrilintide in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cagrilintide in Type 2 Diabetes Drug Details: Cagrilintide is under development...